Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


B&L contact lens marketing settlements have minimal effect on sales because pricing is unchanged.

This article was originally published in The Gray Sheet

Executive Summary

BAUSCH & LOMB/ATTORNEYS GENERAL PACT CODIFIES USE OF ONE TRADE NAME for three types of soft contact lenses previously marketed under different names. Under the terms of a $1.7 mil. settlement with the AGs of 17 states, Bausch & Lomb is required to continue its practice of marketing the three types of lenses under the same trade name. B&L changed to the one-name marketing approach in June.

You may also be interested in...

B&L Contact Lens Settlement Includes Consent To Mail Order Sales

Bausch & Lomb is required to sell its contact lenses through alternative distribution channels, including mail order companies, as part of a $17.5 mil. proposed settlement of a 1994 antitrust class-action lawsuit.

Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts